September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
PRAME: a potential target for immunotherapy in uveal melanoma
Author Affiliations & Notes
  • Gülçin Gezgin
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Sietse J. Luk
    Hematology, Leiden University Medical Center, Leiden, Netherlands
  • Jinfeng Cao
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Mehmet Dogrusoz
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Danielle Krijgsman
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Pieter A. van der Velden
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Gregorius P. M. Luyten
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • J.William Harbour
    Bascom Palmer Eye Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, United States
  • Ekaterina S. Jordanova
    Pathology, Leiden University Medical Center, Leiden, Netherlands
    Gynaecology, VU University Medical Center, Amsterdam, Netherlands
  • Mirjam H. M. Heemskerk
    Hematology, Leiden University Medical Center, Leiden, Netherlands
  • Martine J Jager
    Ophthalmology, Leiden University Medical Center, Leiden, Netherlands
  • Footnotes
    Commercial Relationships   Gülçin Gezgin, None; Sietse Luk, None; Jinfeng Cao, None; Mehmet Dogrusoz, None; Danielle Krijgsman, None; Pieter van der Velden, None; Gregorius P. Luyten, None; J.William Harbour, None; Ekaterina Jordanova, None; Mirjam H. Heemskerk, None; Martine Jager, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Gülçin Gezgin, Sietse J. Luk, Jinfeng Cao, Mehmet Dogrusoz, Danielle Krijgsman, Pieter A. van der Velden, Gregorius P. M. Luyten, J.William Harbour, Ekaterina S. Jordanova, Mirjam H. M. Heemskerk, Martine J Jager; PRAME: a potential target for immunotherapy in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : Uveal melanoma (UM) is the most common intraocular primary malignancy in adults. No effective therapies are yet available for metastatic disease. Preferentially-expressed antigen of melanoma (PRAME) is overexpressed in a variety of malignancies and could be a potential therapeutic target for TCR gene therapy when PRAME peptides are presented by HLA class I. The purpose of this study is to identify whether patients with UM metastases can be candidates for PRAME-specific TCR gene therapy.

Methods : Sixty-four enucleated eyes with primary UM were screened for PRAME gene expression with a RNA microarray. Tumors were dichotomized into low and high PRAME expressing tumors and clinical, histopathological and genetic parameters were compared between both groups. PRAME expression was determined by mRNA Fluorescent in situ hybridization (FISH) in 14 cases of primary UM and in 16 unrelated UM metastases. Additionally, HLA class I expression was determined in the metastases using triple immunofluorescence staining.

Results : Twenty-nine primary UM had a high PRAME gene expression and 35 tumors had low PRAME gene expression. High PRAME expression in primary UM was associated with a larger basal diameter (p=0.005), more ciliary body involvement (p=0.008) and amplification of chromosome 8q (p=0.002). PRAME was present on the primary tumors in 7/14 cases and in 11/16 metastases. HLA class I was expressed in 10/16 metastases. In 8 of the 16 metastases cases concomitant HLA class I and PRAME were present.

Conclusions : PRAME is expressed on primary UM and UM metastases. In 50% of UM patients with metastases, PRAME and HLA class I expression occur together. Therefore, PRAME in UM metastases can be a target for PRAME-specific TCR gene therapy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×